Revvity’s Immunodiagnostic Systems received FDA clearance for a total testosterone automated immunoassay, enabling direct measurement of testosterone markers and streamlining endocrine disorder testing on a single automated platform.
Scopio Labs’ Full-Field Bone Marrow Aspirate Application has received EU IVDR certification, enabling high-throughput digital imaging at 100x resolution to support regulated hematology workflows on the X100 and X100HT platforms.
The FDA has granted Breakthrough Device designation to PreludeDx’s AidaBREAST assay, which uses multi-omic data and AI to assess recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
HistoIndex has partnered with Houston Research Institute and Knowledge Research Center to expand access to AI-driven digital pathology for liver disease diagnostics in Texas and California.
Sapio Sciences has integrated Anthropic's Claude Cowork AI assistant into its platform, enabling scientists to search, retrieve, and analyze R&D data across ELN and LIMS systems through a single conversational interface.
Researchers at Mass General Brigham identified 16 routine lab markers, including cholesterol and glucose, linked to PTSD’s physical effects, suggesting standard tests could aid in assessing the disorder’s multi-organ impact.
The ViaPlex 2-Color Cell Barcoding Kit uses two reactive fluorescent dyes to combine up to 15 distinct cell populations in one tube, reducing reagent use and run time.
The test allows for simultaneous detection of multiple viruses on a sample-to-answer platform designed for immunocompromised patients.
Mayo Clinic researchers have developed a blood test that detected 93% of germ cell tumors—including cases missed by standard markers.
The collaboration focuses on creating sensitive assays for a common genetic risk factor to guide drug development and clinical trials.
Early use of rapid sepsis diagnostics could prevent 36,200 deaths and 84,400 sepsis cases annually in the US, according to a multi-country health economic analysis announced by bioMérieux and conducted by the Office of Health Economics.
Bruker has launched the MyGenius PRO molecular diagnostics system in Europe, offering fully automated, high-throughput PCR testing for infectious diseases with an initial focus on CMV, EBV, and BKV assays for clinical labs.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
A rapid urine test identified effective UTI antibiotics in an average of 5.85 hours, matching standard lab accuracy in a University of Reading study published in the Journal of Antimicrobial Chemotherapy.